After finishing at $35.88 in the prior trading day, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed at $38.29, up 6.72%. In other words, the price has increased by $+2.41 from its previous closing price. On the day, 886945 shares were traded.
Ratios:
Our goal is to gain a better understanding of TARS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.85 and its Current Ratio is at 6.93. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Neutral rating and assigned the stock a target price of $19.
On July 18, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $44.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when Azamian Bobak R. sold 10,415 shares for $30.60 per share. The transaction valued at 318,699 led to the insider holds 26,456 shares of the business.
Neervannan Seshadri sold 4,879 shares of TARS for $149,297 on Mar 18 ’24. The Chief Operating Officer now owns 64,767 shares after completing the transaction at $30.60 per share. On Mar 18 ’24, another insider, Mottiwala Aziz, who serves as the Chief Commercial Officer of the company, sold 4,766 shares for $30.60 each. As a result, the insider received 145,840 and left with 54,075 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 1.44B and an Enterprise Value of 1.24B. For the stock, the TTM Price-to-Sale (P/S) ratio is 82.29 while its Price-to-Book (P/B) ratio in mrq is 6.65. Its current Enterprise Value per Revenue stands at 71.00 whereas that against EBITDA is -9.40.
Stock Price History:
Over the past 52 weeks, TARS has reached a high of $40.40, while it has fallen to a 52-week low of $11.33. The 50-Day Moving Average of the stock is 33.07, while the 200-Day Moving Average is calculated to be 21.77.
Shares Statistics:
The stock has traded on average 792.11K shares per day over the past 3-months and 729.44k shares per day over the last 10 days, according to various share statistics. A total of 34.21M shares are outstanding, with a floating share count of 29.00M. Insiders hold about 22.67% of the company’s shares, while institutions hold 75.18% stake in the company. Shares short for TARS as of Mar 15, 2024 were 7.2M with a Short Ratio of 9.91, compared to 5.66M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 19.19% and a Short% of Float of 20.10%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$1.25 for the current quarter, with a high estimate of -$1.06 and a low estimate of -$1.36, while EPS last year was -$0.88. The consensus estimate for the next quarter is -$1.12, with high estimates of -$0.92 and low estimates of -$1.32.
Analysts are recommending an EPS of between -$3.52 and -$5.44 for the fiscal current year, implying an average EPS of -$4.39. EPS for the following year is -$2.14, with 7 analysts recommending between -$0.35 and -$3.7.
Revenue Estimates
7 analysts predict $17.34M in revenue for the current quarter. It ranges from a high estimate of $20.1M to a low estimate of $14.06M. As of the current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $3.12M, an estimated increase of 455.80% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $106.09M, while the lowest revenue estimate was $75M, resulting in an average revenue estimate of $94.83M. In the same quarter a year ago, actual revenue was $17.45M, up 443.50% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $192.75M in the next fiscal year. The high estimate is $226.51M and the low estimate is $175M. The average revenue growth estimate for next year is up 103.30% from the average revenue estimate for this year.
